Takeda Pharmaceuticals Australia

31 PBAC submissions on file, active 2013–2025. 87% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Vedolizumab
  Gastroenterology · Deferred · 2025$153M
• Brentuximab vedotin
  Oncology · Recommended with restriction · 2025—
• Ixazomib
  Haematology · Recommended with restriction · 2022—
• Lanadelumab
  Immunology · Recommended with restriction · 2024—
• Maribavir
  Infectious disease · Recommended with restriction · 2024—
• Mobocertinib
  Oncology · Recommended with restriction · 2023—
• Alogliptin
  Endocrinology · Recommended with restriction · 2013—
• Alogliptin with metformin
  Endocrinology · Recommended with restriction · 2013—
• Brigatinib
  Oncology · Noted · 2019—
• Fentanyl citrate
  Pain · Recommended with restriction · 2017other sponsor
• Fruquintinib
  Oncology · Recommended with restriction · 2024—
• Teduglutide
  Gastroenterology · Recommended with restriction · 2021—

Therapy area mix

Activity by year

2013 (3) · 2014 (3) · 2015 (3) · 2016 (2) · 2018 (2) · 2019 (1) · 2020 (2) · 2021 (3) · 2022 (2) · 2023 (2) · 2024 (6) · 2025 (2)

Rejection patterns

Across 3 Not recommended decisions on file.

• 1×poor quality of clinical data
• 1×uncertainty regarding non-inferiority in comparative safety
• 1×uncertain equi-effective doses not accounting for dose titration rates
• 1×potential for net harm due to overdose risk
• 1×safety issues identified by ACSOM and ANZCA regarding packaging design and potential for misuse and diversion